Artificial intelligence is beginning to reshape how drug companies interact with the Food and Drug Administration, though most changes so far have been limited.

Elsa” is the FDA’s new anthropomorphized AI tool which, the FDA hopes, will speed up clearances, licenses, and approvals ...

The FDA plans to "unleash AI" on new drug evaluations in order to "radically increase efficiency in the review process." ...

A new article in the Journal of the American Medical Association said the FDA will implement AI into multiple processes.

The Food and Drug Administration (FDA) is looking to AI to solve the problem of lengthy approval processes, as the Trump ...

Learn more about the generative AI technology that will be used at the Food and Drug Administration (FDA) to speed up reviews ...

The Food and Drug Administration has gone all in on AI since Martin Makary, M.D., took over the agency, most recently ...

The FDA has launched a pilot program using generative AI to help expedite the review of drug and device applications, part of a sweeping modernization effort by the agency. The initiative, led by FDA ...

AI is slowly permeating all corners of the federal government, including the Food and Drug Administration, where, according ...

FDA Commissioner Marty Makary and CBER Director Vinay Prasad published an article in JAMA on Tuesday outlining the FDA’s ...